Marketwire (May 16, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
438 people get NLNK articles and Market Currents by email alert.
Get email alerts on NLNK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Marketwire (May 16, 2013)
-
Marketwire (May 6, 2013)
-
-
PR Newswire (Apr 25, 2013)
-
-
-
Marketwire (Feb 28, 2013)
-
PR Newswire (Feb 25, 2013)
-
-
-
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Jan 29, 2013)
-
PR Newswire (Jan 3, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
IPO Preview: NewLink GeneticsIPOdesktop • Tue, Nov 8, 2011
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3 Cancer Immunotherapy Biotechs With Catalysts For 2012Chemistfrog • Wed, Nov 16, 2011 -
5 IPOs On Tap This WeekRenaissance Capital IPO Research • Mon, Nov 7, 2011 -
The IPO Buzz: Stepping On The AcceleratorIPOScoop • Mon, Nov 7, 2011 -
Global IPO Market Bounces BackRenaissance Capital IPO Research • Fri, Oct 28, 2011
-
Marketwire (May 16, 2013)
-
Marketwire (May 16, 2013)
-
Marketwire (May 6, 2013)
-
PR Newswire (Apr 25, 2013)
-
Marketwire (Feb 28, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Jan 29, 2013)
-
PR Newswire (Jan 3, 2013)
-
PR Newswire (Nov 7, 2012)
-
Marketwire (Oct 31, 2012)
-
PR Newswire (Oct 2, 2012)
NLNK vs. ETF Alternatives
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 3:23 PM NewLink Genetics (NLNK +2.1%) moves up after being selected for addition to the NASDAQ Biotechnology Index, effective prior to the market open on Monday. Comment! [Healthcare, On the Move]
- Monday, May 6, 11:31 AM NewLink Genetics (NLNK -3.3%) slips after its Q1 misses estimates across the board this morning. Net losses grew on a decline in grant revenue and a jump in R&D expenses, primarily due to increased manufacturing and clinical trial costs. Looking at its pipeline, the company says it anticipates completing patient accrual for its Impress trial of algenpantucel-L for surgically resected pancreatic cancer, and it recently presented preclinical results for its second IDO pathway inhibitor drug candidate, NLG919, at the American Association for Cancer Research annual meeting. Based on the data, it plans to initiate clinical trials later this year. Comment! [Healthcare, On the Move, Earnings]
- Monday, May 6, 7:51 AM NewLink Genetics (NLNK): Q1 EPS of -$0.33 misses by $0.05. Revenue of $302K misses by $108K. (PR) Comment! [Earnings, Breaking News]
- Thursday, February 28, 9:43 AM NewLink Genetics (NLNK): Q4 EPS of -$0.30 beats by $0.02. Revenue of $299K misses by $110K. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, November 14, 2012, 1:32 PM Newlink Genetics (NLNK +4.3%) gains today after European regulators grant orphan drug status for Algenpantucel-L, the company's off-the-shelf product candidate for treatment of pancreatic cancer. The drug is currently is in Phase III testing in the U.S. Comment! [Global & FX, Healthcare, On the Move]
- Monday, June 4, 2012, 12:59 PM ASCO oncology conference: NewLink Genetics (NLNK) -6.3% despite patients enjoying improved survival rates in a Phase II trial of the company's algenpantucel-L treatment for pancreatic cancer. NewLink Genetics has also disclosed positive results in early stage trials of two other drugs (I, II). Comment! [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.